#2 - Pfizer (NYSE:PFE)
Pfizer (NYSE:PFE) has a 62.8% Net Impact Ratio as of this writing. And like Moderna, the rating largely stems from the company’s impact on reducing physical diseases. However, unlike Moderna, Pfizer has a wider spectrum of vaccines and therapeutics in the market.
That is one reason that PFE stock has not suffered the same misfortune as Moderna. However, Pfizer stock has still dropped over 13% from its 52-week high. Nevertheless, Pfizer still is considered a consensus buy with analysts. And the company received two potentially bullish pieces of news. First, Pfizer has asked the FDA to review approving its Covid-19 vaccine for children under five. Also, France announced it will begin using Pfizer’s coronavirus pill, making it the first European Union country to use the antiviral treatment.
With companies such as Pfizer, investing comes down to the company’s pipeline. In the case of Pfizer, the company has 29 programs in Phase 3 testing as of November 2, 2021. That means it’s highly likely that Pfizer will have other sources of revenue when the company’s revenue from its Covid-19 portfolio begins to level off.
About Pfizer
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More - Current Price
- $28.64
- Consensus Rating
- Hold
- Ratings Breakdown
- 6 Buy Ratings, 9 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $35.86 (25.2% Upside)
